Tau PET imaging of the living brain is expected to be used not only for diagnosis of these diseases named as tauopathies but also for subject screening in clinical studies of therapeutic drugs or for evaluation of treatment effects of new anti-dementia drugs that prevent neuronal cell death by inhibiting tau accumulation. This evidence concerns the gene MAPT and dementia.